New Zealand

5 Vaccines Approved for Use in New Zealand

Protein Subunit

Novavax

Nuvaxovid

Approved in 40 countries
22 trials in 14 countries
Approval Source: ir.novavax.com
RNA

Pfizer/BioNTech

Comirnaty

Approved in 149 countries
100 trials in 31 countries
Approval Source: medsafe.govt.nz
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Ad26.COV2.S

Approved in 111 countries
23 trials in 23 countries
Approval Source: reuters.com
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 149 countries
73 trials in 34 countries
Approval Source: reuters.com
Non Replicating Viral Vector

Janssen (Johnson & Johnson)

Jcovden

Approved in 113 countries
26 trials in 25 countries
Approval Source: reuters.com

10 in Clinical Trials in New Zealand

Protein Subunit

Jiangsu Rec-Biotechnology Co Ltd

ReCOV

6 trials in 3 countries
Protein Subunit

SK Bioscience Co Ltd

GBP510

6 trials in 6 countries
Non Replicating Viral Vector

Oxford/AstraZeneca

Vaxzevria

Approved in 149 countries
73 trials in 34 countries
Inactivated

Valneva

VLA2001

Approved in 33 countries
9 trials in 4 countries
Inactivated

Valneva

VLA2101

Protein Subunit

VaxForm

CoV2-OGEN1

Protein Subunit

Yisheng Biopharma

PIKA COVID-19 Vaccine

3 trials in 1 country
Protein Subunit

Novavax

Nuvaxovid

Approved in 40 countries
22 trials in 14 countries
Protein Subunit

SK Bioscience Co Ltd

SKYCovione

Approved in 1 country
7 trials in 6 countries
Protein Subunit

Novavax

ICC Vaccine

3 trials in 2 countries